160893-07-2

Basic information

• Product Name: 2-Chloro-5-Methoxyquinoline
• Synonyms: 2-Chloro-5-Methoxyquinoline
• CAS NO: 160893-07-2
• Molecular Formula: C₁₀H₈ClNO
• Molecular Weight: 193.62962
• Mol File: 160893-07-2.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-Chloro-5-Methoxyquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-Methoxyquinoline(160893-07-2)
• EPA Substance Registry System: 2-Chloro-5-Methoxyquinoline(160893-07-2)

Safety Data

• Hazardous Substances Data: 160893-07-2(Hazardous Substances Data)

Usage

General Description

2-Chloro-5-Methoxyquinoline is a chemical compound with the molecular formula C10H7NOCl. It is a derivative of quinoline and is characterized by a chlorine atom and a methoxy group attached to the quinoline ring. 2-Chloro-5-Methoxyquinoline has been found to possess various biological activities, including antimicrobial and antifungal properties. It is also used in the synthesis of pharmaceuticals and other organic compounds. Additionally, 2-Chloro-5-Methoxyquinoline has potential applications in the study of inflammation and oxidative stress due to its ability to modulate certain pathways involved in these processes. Overall, this chemical compound has diverse applications and potential for further research and development in the pharmaceutical and biomedical fields.

Upstream product

• 611-34-7 5-Aminoquinoline 
• 607-34-1 5-nitroquinoline 
• 160893-04-9 5-methoxy-2(1H)-quinolinone 
• 6931-19-7 5-methoxyquinoline 
• 578-67-6 quinolin-5-ol 
• 90924-16-6 5--methoxyquinoline N--oxide 
• 186581-53-3 diazomethane 
• 124467-35-2 2-chloro-5-hydroxyquinoline 

Relevant articles and documents

Design and synthesis of new 2-anilinoquinolines bearing N-methylpicolinamide moiety as potential antiproliferative agents

A series of new 2-anilinoquinolines 6a–o possessing the substantial N-methylpicolinamide motif at C5 has been designed and synthesized as sorafenib analogs. The antiproliferative activities of the target compounds were preliminarily appraised against a panel of three human cancer cell lines (MCF-7, SK-BR3, and HCT116), and a selected array was further tested over a panel of approximately 60 cancer cell lines at NCI at 10?μM concentration. Interestingly, compounds 6c, 6d, 6j, 6k, and 6l showed promising selective anticancer activities (growth inhibition >80%) toward certain cancer cells at 10?μM testing dose. Compounds 6d and 6j were advanced to five-dose testing mode to determine their GI50 values and compared with our previously reported ureidoquinoline B and sorafenib as reference compounds. The 4-chloro-3-trifluoromethylaniline derivative 6j manifested superior potency than both compound B and sorafenib over eleven and eight cell lines, respectively. It showed GI50 values of 0.36, 0.66, 0.68, and 0.60?μM against the breast MDA-MB-468, renal A498, and melanoma SK-MEL-5 and UACC-62 cell lines, respectively. Moreover, both 6d and 6j exerted low cytotoxic effects against HFF-1 normal cell line. Furthermore, compounds 6d and 6j were tested against both B-RafV600E and C-Raf kinases and displayed modest inhibitory activities, which were justified by molecular docking study. Compound 6j could serve as a promising candidate for further development of potent anticancer chemotherapeutics.

NOVEL QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCER CONTAINING THE SAME

The present invention refers to an excellent cancer antiproliferative potency relative to the quinoline compounds, a pharmaceutically acceptable salt, or hydrate and, number of active ingredient containing bath method and pharmaceutical composition for the prevention or treatment of cancer disease relates to search, said present invention according to compound, a pharmaceutically acceptable salt thereof, or hydrate number and number and mutant kinase protein kinase activity number of excellent cancer billion billion number activity and thus, new anticancer number is useful as the effective component can be. (by machine translation)

Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives

Abstract New 2-amido and ureido quinoline derivatives substituted with 2-N-methylamido-pyridin-4-yloxy group at the 5-position of quinoline (18 final compounds) have been designed and synthesized as anticancer sorafenib congeners. Among the synthesized de